Academic Journal
EFFECT OF VALSARTAN AND OLMESARTAN ON POLYMORPHISM OF NO-SYNTHASE GENES ; ВПЛИВ ВАЛСАРТАНУ І ОЛМЕСАРТАНУ НА ПОЛІМОРФІЗМ ГЕНІВ NO-СИНТАЗИ
| العنوان: | EFFECT OF VALSARTAN AND OLMESARTAN ON POLYMORPHISM OF NO-SYNTHASE GENES ; ВПЛИВ ВАЛСАРТАНУ І ОЛМЕСАРТАНУ НА ПОЛІМОРФІЗМ ГЕНІВ NO-СИНТАЗИ |
|---|---|
| المؤلفون: | Підручна, С. Р., Янчишина, М. А., Мудра, Є. М., Теренда, О. А. |
| المصدر: | Achievements of Clinical and Experimental Medicine; No. 4 (2024); 52-58 ; Достижения клинической и экспериментальной медицины; № 4 (2024); 52-58 ; Здобутки клінічної і експериментальної медицини; № 4 (2024); 52-58 ; 2415-8836 ; 1811-2471 ; 10.11603/1811-2471.2024.v.i4 |
| بيانات النشر: | Ternopil National Medical University |
| سنة النشر: | 2024 |
| المجموعة: | Scientific Journals of Ternopil State Medical University / Наукові журнали Тернопільського державного медичного університету імені І.Я.Горбачевського |
| مصطلحات موضوعية: | arterial hypertension, nitric oxide synthase, gene polymorphism, personalized medicine, antihypertensive drugs, артеріальна гіпертензія, NO-синтаза, поліморфізм генів, персоналізована медицина, антигіпертензивні препарати |
| الوصف: | SUMMARY. The aim – to analyze current data on the impact of valsartan and olmesartan on nitric oxide synthase gene polymorphisms and its consequences for the effectiveness of arterial hypertension treatment. Material and Methods. The study material comprised data from the literature of the past 5-10 years related to arterial hypertension, nitric oxide synthase, gene polymorphism, and the effects of antihypertensive drugs. Results. While valsartan and olmesartan do not directly affect nitric oxide synthase activity, they indirectly increase nitric oxide production. The effectiveness of these drugs depends on the individual genetic characteristics of the patient, particularly on nitric oxide synthase gene polymorphisms. It has been shown that a genetic test can help select the optimal dose and combination of drugs for each patient with arterial hypertension. This allows for increased treatment efficacy and reduced risk of adverse side effects. However, further research and the development of standard protocols are necessary for the widespread use of genetic tests in clinical practice. Thus, understanding the interaction between drugs and genetic factors opens new perspectives for personalized therapy of arterial hypertension. Conclusions: Valsartan and olmesartan indirectly stimulate NO production. Nitric oxide synthase gene polymorphism affects the effectiveness of these drugs. A genetic test allows for individualized therapy for patients with arterial hypertension, increasing its efficacy and reducing the risk of side effects. However, additional research is needed for the widespread use of genetic tests. Key Points: Valsartan and olmesartan affect NO through angiotensin II receptors. Nitric oxide synthase gene polymorphism affects the body’s response to these drugs. A genetic test helps select the optimal treatment for each patient. Further research is necessary for the wider use of genetic tests in clinical practice. This approach allows for the personalization of arterial hypertension treatment and improves ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Ukrainian |
| Relation: | https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/15026/13830 |
| DOI: | 10.11603/1811-2471.2024.v.i4.15026 |
| الاتاحة: | https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/15026 https://doi.org/10.11603/1811-2471.2024.v.i4.15026 |
| Rights: | Авторське право (c) 2024 Здобутки клінічної і експериментальної медицини |
| رقم الانضمام: | edsbas.6A0DC592 |
| قاعدة البيانات: | BASE |
| DOI: | 10.11603/1811-2471.2024.v.i4.15026 |
|---|